source
- Zura Bio’s Phase 2 trial of tibulizumab fails, shares plungeZura Bio announced that its experimental drug tibulizumab did not meet efficacy endpoints in a Phase 2 study of a painful skin disorder. The company said that both dose levels performed no better t…
- Pentagon removes WuXi AppTec from Chinese military companies list, but risk of redesignation remainsThe U.S. Department of Defense announced that WuXi AppTec, a Shanghai-based contract research and manufacturing firm, has been taken off the Pentagon’s list of Chinese entities tied to the People’s…